[HTML][HTML] Generating and measuring effective vaccine-elicited HIV-specific CD8+ T cell responses
GM Borgo, RL Rutishauser - Current Opinion in HIV and AIDS, 2023 - journals.lww.com
Identifying a vaccine capable of generating durable T cell responses that target mutationally
vulnerable epitopes and that can rapidly intercept infecting or rebounding virus remains a …
vulnerable epitopes and that can rapidly intercept infecting or rebounding virus remains a …
Harnessing recent advances in synthetic DNA and electroporation technologies for rapid vaccine development against COVID-19 and other emerging infectious …
DNA vaccines are considered as a third-generation vaccination approach in which antigenic
materials are encoded as DNA plasmids for direct in vivo production to elicit adaptive …
materials are encoded as DNA plasmids for direct in vivo production to elicit adaptive …
CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits
A Koornneef, K Vanshylla, G Hardenberg… - Nature …, 2024 - nature.com
One of the strategies towards an effective HIV-1 vaccine is to elicit broadly neutralizing
antibody responses that target the high HIV-1 Env diversity. Here, we present an HIV-1 …
antibody responses that target the high HIV-1 Env diversity. Here, we present an HIV-1 …
Co-immunization of DNA and protein in the same anatomical sites induces superior protective immune responses against SHIV challenge
We compare immunogenicity and protective efficacy of an HIV vaccine comprised of env and
gag DNA and Env (Envelope) proteins by co-administration of the vaccine components in …
gag DNA and Env (Envelope) proteins by co-administration of the vaccine components in …
Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
R Lassaunière, C Polacek, GJ Gram, A Frische… - npj Vaccines, 2021 - nature.com
New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine
platform for preparedness against emerging viral pathogens. Applying platform optimization …
platform for preparedness against emerging viral pathogens. Applying platform optimization …
Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV …
I Frank, SS Li, N Grunenberg, ET Overton… - The Lancet …, 2024 - thelancet.com
Background An effective HIV vaccine will most likely need to have potent immunogenicity
and broad cross-subtype coverage. The aim of the HIV Vaccine Trials Network (HVTN) 124 …
and broad cross-subtype coverage. The aim of the HIV Vaccine Trials Network (HVTN) 124 …
Rational vaccine design in times of emerging diseases: The critical choices of immunological correlates of protection, vaccine antigen and immunomodulation
Vaccines are the most effective medical intervention due to their continual success in
preventing infections and improving mortality worldwide. Early vaccines were developed …
preventing infections and improving mortality worldwide. Early vaccines were developed …
Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV
S D'haese, C Lacroix, F Garcia, M Plana, S Ruta… - Journal of Controlled …, 2021 - Elsevier
Over the last few years, immunotherapy for HIV in general and therapeutic vaccination in
particular, has received a tremendous boost, both in preclinical research and in clinical …
particular, has received a tremendous boost, both in preclinical research and in clinical …
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in …
Z Moodie, E Andersen-Nissen, N Grunenberg… - Plos …, 2024 - journals.plos.org
Background Adjuvants are widely used to enhance and/or direct vaccine-induced immune
responses yet rarely evaluated head-to-head. Our trial directly compared immune responses …
responses yet rarely evaluated head-to-head. Our trial directly compared immune responses …
[HTML][HTML] Robust antibody and cellular responses induced by DNA-only vaccination for HIV
SC De Rosa, S Edupuganti, Y Huang, X Han… - JCI insight, 2020 - ncbi.nlm.nih.gov
BACKGROUND HVTN 098, a randomized, double-blind, placebo-controlled trial, evaluated
the safety, tolerability, and immunogenicity of PENNVAX-GP HIV DNA vaccine, administered …
the safety, tolerability, and immunogenicity of PENNVAX-GP HIV DNA vaccine, administered …